AR090605A1 - Un antagonista del receptor h3 para uso en el tratamiento de la enfermedad de alzheimer - Google Patents
Un antagonista del receptor h3 para uso en el tratamiento de la enfermedad de alzheimerInfo
- Publication number
- AR090605A1 AR090605A1 ARP130101105A ARP130101105A AR090605A1 AR 090605 A1 AR090605 A1 AR 090605A1 AR P130101105 A ARP130101105 A AR P130101105A AR P130101105 A ARP130101105 A AR P130101105A AR 090605 A1 AR090605 A1 AR 090605A1
- Authority
- AR
- Argentina
- Prior art keywords
- disease
- alzheimer
- treatment
- receiver antagonist
- antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Esta descripción se refiere a métodos de uso de la 2-(ciclohexilmetil)-N-{2-[(2S)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolina-7-sulfonamida en una terapia modificadora de la enfermedad para la enfermedad de Alzheimer, otras tauopatías y enfermedades neurodegenerativas relacionadas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12305415.7A EP2647377A1 (en) | 2012-04-06 | 2012-04-06 | Use of an h3 receptor antagonist for the treatment of alzheimer's disease |
US201361792635P | 2013-03-15 | 2013-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR090605A1 true AR090605A1 (es) | 2014-11-26 |
Family
ID=46001073
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130101105A AR090605A1 (es) | 2012-04-06 | 2013-04-04 | Un antagonista del receptor h3 para uso en el tratamiento de la enfermedad de alzheimer |
Country Status (17)
Country | Link |
---|---|
US (2) | US20150031893A1 (es) |
EP (2) | EP2647377A1 (es) |
JP (1) | JP6143842B2 (es) |
KR (1) | KR20150000490A (es) |
CN (1) | CN104363911A (es) |
AR (1) | AR090605A1 (es) |
AU (1) | AU2013244928B2 (es) |
BR (1) | BR112014024736A2 (es) |
CA (1) | CA2868481A1 (es) |
ES (1) | ES2618924T3 (es) |
MX (1) | MX354020B (es) |
PL (1) | PL2833887T3 (es) |
RU (1) | RU2014144615A (es) |
SG (2) | SG11201406093VA (es) |
TW (1) | TW201402119A (es) |
UY (1) | UY34734A (es) |
WO (1) | WO2013150150A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2647377A1 (en) | 2012-04-06 | 2013-10-09 | Sanofi | Use of an h3 receptor antagonist for the treatment of alzheimer's disease |
CN105764510A (zh) * | 2013-09-09 | 2016-07-13 | 赛诺菲 | H3受体拮抗剂与胆碱酶抑制剂组合用于阿尔茨海默氏病治疗中的用途 |
CN114053289B (zh) * | 2020-08-06 | 2023-06-27 | 北京箭牧科技有限公司 | 瑞德西韦在制备预防和治疗神经系统退行性疾病药物中的应用 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004532834A (ja) | 2001-03-23 | 2004-10-28 | イーライ・リリー・アンド・カンパニー | ヒスタミンh3受容体アンタゴニストである非イミダゾール系アリールアルキルアミン化合物、その製造および治療的使用 |
US20060052597A1 (en) | 2002-10-22 | 2006-03-09 | Best Desmond J | Aryloxyalkylamine derivatives as h3 receptor ligands |
GB0224557D0 (en) | 2002-10-22 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
KR100765027B1 (ko) | 2002-12-20 | 2007-10-09 | 글락소 그룹 리미티드 | 신경 장애 치료용 벤즈아제핀 유도체 |
US20050031651A1 (en) | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
US20060293298A1 (en) | 2003-04-10 | 2006-12-28 | Bamford Mark J | Compounds |
TW200503713A (en) | 2003-04-23 | 2005-02-01 | Glaxo Group Ltd | Novel compounds |
TW200514781A (en) | 2003-07-18 | 2005-05-01 | Glaxo Group Ltd | Novel compounds |
GB0324159D0 (en) | 2003-10-15 | 2003-11-19 | Glaxo Group Ltd | Novel compounds |
GB0329214D0 (en) | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Novel compounds |
WO2005118548A1 (en) | 2004-03-01 | 2005-12-15 | Actelion Pharmaceuticals Ltd | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives |
GB0408083D0 (en) | 2004-04-08 | 2004-05-12 | Glaxo Group Ltd | Novel compounds |
FR2870846B1 (fr) | 2004-05-25 | 2006-08-04 | Sanofi Synthelabo | Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique |
TW200611701A (en) | 2004-06-18 | 2006-04-16 | Glaxo Group Ltd | Novel compounds |
GB0418267D0 (en) | 2004-08-16 | 2004-09-15 | Glaxo Group Ltd | Novel compounds |
GB0420831D0 (en) | 2004-09-17 | 2004-10-20 | Glaxo Group Ltd | Novel compounds |
WO2006040192A1 (en) | 2004-10-15 | 2006-04-20 | Glaxo Group Limited | Pyrrolidine derivatives as histamine receptors ligands |
US20090306052A1 (en) | 2004-12-07 | 2009-12-10 | Glaxo Group Limited | Indenyl derivatives and use thereof for the treatment of neurological disorders |
JP2008533117A (ja) | 2005-03-14 | 2008-08-21 | グラクソ グループ リミテッド | ヒスタミンh3受容体に対して親和性を有する縮合チアゾール誘導体 |
GB0513886D0 (en) | 2005-07-06 | 2005-08-10 | Glaxo Group Ltd | Novel compounds |
EP1790646A1 (fr) | 2005-11-24 | 2007-05-30 | Sanofi-Aventis | Derives de Isoquinoline et Benzo[h]Isoquinoline, leur preparation et leur utilisation en thérapeutique en tant qu'antagonistes du recepteur de l'histamine H3. |
ES2366958T3 (es) | 2006-06-23 | 2011-10-27 | Laboratorios Del Dr. Esteve, S.A. | Combinación de un inhibidor de la colinesterasa y un compuesto con afinidad por el receptor 5-ht6. |
CL2008000597A1 (es) | 2007-03-01 | 2008-09-05 | Glaxo Group Ltd | Forma de dosificacion que comprende 6-(3-ciclobutil-2,3,4,5-tetrahidro-1h-benzo[d]azepin-7-il oxi)-n-metil nicotinamida, un estabilizante y un excipiente; procedimiento de preparacion; y su uso para tratar enfermedades neurologicas. |
ES2384414T3 (es) | 2007-09-06 | 2012-07-04 | Glaxo Group Limited | Derivado de piperazina que tiene afinidad por el receptor H3 de histamina |
UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
JP2012500823A (ja) | 2008-08-29 | 2012-01-12 | グラクソ グループ リミテッド | 1−イソプロピル−4−{[4−(テトラヒドロ−2h−ピラン−4−イルオキシ)フェニル]カルボニル}ヘキサヒドロ−1h−1,4−ジアゼピンまたはその塩を含んでなる剤形 |
WO2010026113A1 (en) * | 2008-09-03 | 2010-03-11 | Evotec Neurosciences Gmbh | Acyl- and sufonyl tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists |
EP2445899B1 (en) | 2009-06-26 | 2016-05-11 | Sanofi | Novel fumarate salts of a histamine h3 receptor antagonist |
AR077859A1 (es) | 2009-08-12 | 2011-09-28 | Boehringer Ingelheim Int | Compuestos para el tratamiento de trastornos del snc |
WO2011051423A1 (en) | 2009-11-02 | 2011-05-05 | Glaxo Group Limited | Treatment or prophylaxis of dementia, neurodegenerative disorders, schizophrenia, adhd, somnolence or epilepsy |
FR2976286B1 (fr) | 2011-06-08 | 2013-05-24 | Servier Lab | 4-{3-[trans-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide, son procede de preparation et les compositions pharmaceutiques qui le contiennent |
EP2647377A1 (en) | 2012-04-06 | 2013-10-09 | Sanofi | Use of an h3 receptor antagonist for the treatment of alzheimer's disease |
EP2745876A1 (en) | 2012-12-21 | 2014-06-25 | Prous Institute for Biomedical Research, S.A. | Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives |
CN105764510A (zh) * | 2013-09-09 | 2016-07-13 | 赛诺菲 | H3受体拮抗剂与胆碱酶抑制剂组合用于阿尔茨海默氏病治疗中的用途 |
-
2012
- 2012-04-06 EP EP12305415.7A patent/EP2647377A1/en not_active Ceased
-
2013
- 2013-04-03 TW TW102112006A patent/TW201402119A/zh unknown
- 2013-04-04 AR ARP130101105A patent/AR090605A1/es unknown
- 2013-04-05 EP EP13714652.8A patent/EP2833887B1/en not_active Not-in-force
- 2013-04-05 PL PL13714652T patent/PL2833887T3/pl unknown
- 2013-04-05 CN CN201380029300.6A patent/CN104363911A/zh active Pending
- 2013-04-05 BR BR112014024736A patent/BR112014024736A2/pt not_active IP Right Cessation
- 2013-04-05 KR KR1020147029735A patent/KR20150000490A/ko not_active Application Discontinuation
- 2013-04-05 RU RU2014144615A patent/RU2014144615A/ru unknown
- 2013-04-05 MX MX2014011992A patent/MX354020B/es active IP Right Grant
- 2013-04-05 JP JP2015503896A patent/JP6143842B2/ja not_active Expired - Fee Related
- 2013-04-05 ES ES13714652.8T patent/ES2618924T3/es active Active
- 2013-04-05 SG SG11201406093VA patent/SG11201406093VA/en unknown
- 2013-04-05 AU AU2013244928A patent/AU2013244928B2/en not_active Ceased
- 2013-04-05 CA CA2868481A patent/CA2868481A1/en not_active Abandoned
- 2013-04-05 SG SG10201801200PA patent/SG10201801200PA/en unknown
- 2013-04-05 UY UY0001034734A patent/UY34734A/es not_active Application Discontinuation
- 2013-04-05 WO PCT/EP2013/057241 patent/WO2013150150A1/en active Application Filing
-
2014
- 2014-10-03 US US14/506,089 patent/US20150031893A1/en not_active Abandoned
-
2015
- 2015-10-01 US US14/872,812 patent/US9789102B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP2647377A1 (en) | 2013-10-09 |
BR112014024736A2 (pt) | 2017-07-11 |
CA2868481A1 (en) | 2013-10-10 |
US20150031893A1 (en) | 2015-01-29 |
AU2013244928B2 (en) | 2017-08-10 |
ES2618924T3 (es) | 2017-06-22 |
JP2015516963A (ja) | 2015-06-18 |
US20160101099A1 (en) | 2016-04-14 |
PL2833887T3 (pl) | 2017-06-30 |
KR20150000490A (ko) | 2015-01-02 |
US9789102B2 (en) | 2017-10-17 |
AU2013244928A1 (en) | 2014-10-30 |
MX354020B (es) | 2018-02-08 |
SG11201406093VA (en) | 2014-10-30 |
SG10201801200PA (en) | 2018-04-27 |
WO2013150150A1 (en) | 2013-10-10 |
CN104363911A (zh) | 2015-02-18 |
UY34734A (es) | 2013-11-29 |
RU2014144615A (ru) | 2016-05-27 |
EP2833887B1 (en) | 2016-12-28 |
EP2833887A1 (en) | 2015-02-11 |
JP6143842B2 (ja) | 2017-06-07 |
MX2014011992A (es) | 2015-05-08 |
TW201402119A (zh) | 2014-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2015000578A1 (es) | Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer. | |
CY1125068T1 (el) | Ενωσεις τετραϋποκατεστημενου αλκενιου και χρηση αυτων | |
EA201390977A1 (ru) | Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона | |
EA201490194A1 (ru) | Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака | |
EA201391351A1 (ru) | Способы повышения эффективности folr1 терапии рака | |
CO7200273A2 (es) | Combinaciones farmaceúticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa | |
PH12017500164A1 (en) | Optionally fused heterocyclyl - substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | |
CL2013002053A1 (es) | Compuestos derivados de heterociclicos, antagonistas del receptor de glucagon; composicion farmaceutica que lo comprende y su uso en el tratamiento de diabetes y enfermedades metabolicas. pct | |
EA201492040A1 (ru) | Бициклически замещённые урацилы и их применение | |
CL2017001756A1 (es) | Régimen de dosificación para antagonistas de madcam. | |
CL2017000050A1 (es) | Terapia de combinación para el cáncer | |
PH12016502353A1 (en) | Pharmaceutical composition | |
CL2012001293A1 (es) | Uso del compuesto 2-(4-metilfenil)-6-(metil)quinolina para inhibor la agragacion de la proteina tau en una persona dque sufre alzheimer | |
SG11201601306QA (en) | An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease | |
EA201590823A1 (ru) | 6-((s)-1-{1-[5-(2-гидроксиэтокси)пиридин-2-ил]-1h-пиразол-3-ил}этил)-3h-1,3-бензотиазол-2-он в качестве антагониста tarp-гамма 8-зависимого ampa-рецептора | |
CL2015001881A1 (es) | Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición. | |
AR090605A1 (es) | Un antagonista del receptor h3 para uso en el tratamiento de la enfermedad de alzheimer | |
DK3402537T3 (da) | Kvantitativ PET-afbildning af vævsfaktorekspression under anvendelse af 18-F mærket, aktiv positions-inhiberet faktor VII | |
CO6480943A2 (es) | Nuevas sales de fumarato de un antagonista del receptor de histamina h3 | |
EA201490938A1 (ru) | Производные спиротиенопиранпиперидина в качестве антагонистов рецептора orl-1 для применения для лечения алкогольной зависимости и злоупотребления алкоголем | |
EA201301080A1 (ru) | Применение солей 3-карбокси-n-этил-n,n-диметилпропан-1-аммония при лечении сердечно-сосудистого заболевания | |
AR104931A1 (es) | Métodos para tratar cáncer usando anticuerpos anti-ox40 y antagonistas de unión al eje pd-1 | |
EA201491226A1 (ru) | НОВОЕ ТЕРАПЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ АНТАГОНИСТОВ РЕЦЕПТОРОВ p75 | |
MA40553A (fr) | Dérivés de pyrimidine substitués par un hétérocyclyle éventuellement condensés utiles pour le traitement des maladies inflammatoires, métaboliques, oncologiques et auto-immunes | |
RU2008133842A (ru) | Применение триптофана для лечения задержки психоречевого развития при нервно-психических заболеваниях |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |